There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AmerisourceBergen (ABC – Research Report), Xenon (XENE – Research Report) and Replimune Group (REPL – Research Report) with bullish sentiments.
AmerisourceBergen (ABC)
In a report released today, Kevin Caliendo from UBS maintained a Buy rating on AmerisourceBergen, with a price target of $190.00. The company’s shares closed last Tuesday at $166.11.
According to TipRanks.com, Caliendo is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AmerisourceBergen with a $183.80 average price target, a 9.9% upside from current levels. In a report released today, Evercore ISI also initiated coverage with a Buy rating on the stock with a $185.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Xenon (XENE)
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Xenon, with a price target of $51.00. The company’s shares closed last Tuesday at $38.90, close to its 52-week high of $41.39.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $50.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABC:
- AmerisourceBergen to change name to Cencora
- AmerisourceBergen plans to change name to Cencora
- AmerisourceBergen price target raised to $190 from $170 at Argus
- AmerisourceBergen price target raised to $199 from $195 at Baird
- Billionaire Leon Cooperman Says the Bear Market Is Expected to Continue in 2023 — Here Are 2 ‘Safe Haven’ Stocks That Analysts Like
